Regeneron Pharmaceuticals (REGN) Treasury Shares (2010 - 2026)

Regeneron Pharmaceuticals has reported Treasury Shares for 13 years, with the latest figure at $19.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 19.7% year-over-year to $19.4 billion; the trailing twelve-month figure through Mar 2026 stood at $19.4 billion (up 19.7% YoY), and the FY2025 full-year result was $18.6 billion, up 22.72% from the prior year.
• Treasury Shares for Q1 2026 stood at $19.4 billion, up from $18.6 billion in the prior quarter.
• The five-year high for Treasury Shares was $34.7 million in Q1 2026, with the low at $900000.0 in Q1 2023.
• Average Treasury Shares over 5 years is $19.4 million, with a median of $25.1 million recorded in 2023.
• Year-over-year, Treasury Shares soared 33.79% in 2022 and rose 14.36% in 2024.
• Tracing REGN's Treasury Shares over 5 years: stood at $10.4 billion in 2022, then gained by 21.32% to $12.6 billion in 2023, then grew by 20.76% to $15.2 billion in 2024, then climbed by 22.72% to $18.6 billion in 2025, then increased by 4.3% to $19.4 billion in 2026.
• The last three Treasury Shares figures came in at $19.4 billion (Q1 2026), $18.6 billion (Q4 2025), and $17.9 billion (Q3 2025), per Business Quant data.

Peer Comparison